Insulin-like Growth Factor (IGF-I) induced muscle glucose uptake and interstitial IGF-1 concentrations. Placebo controlled, crossover study of the effect of sc rhIGF-I (Increlex) administration on glucose infusion rate (whole body glucose utilization) and interstitial muscle IGF-1 concentrations under euglycemic clamp conditions in T1DM adolescents and young adults.

Trial Profile

Insulin-like Growth Factor (IGF-I) induced muscle glucose uptake and interstitial IGF-1 concentrations. Placebo controlled, crossover study of the effect of sc rhIGF-I (Increlex) administration on glucose infusion rate (whole body glucose utilization) and interstitial muscle IGF-1 concentrations under euglycemic clamp conditions in T1DM adolescents and young adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs Mecasermin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2012 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Additional lead trial investigator (Bang P) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top